The majority of metastatic EGFR-mutant lung adenocarcinomas (LUAD) harbor one or more co-mutations, and TP53 is a common co-mutated gene in EGFR-mutant NSCLC, accounting for 55–65% of cases [13,14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.